NXTC
Price
$0.51
Change
-$0.00 (-0.00%)
Updated
May 23 closing price
Capitalization
14.24M
66 days until earnings call
REPL
Price
$8.35
Change
-$0.41 (-4.68%)
Updated
May 23 closing price
Capitalization
643.67M
66 days until earnings call
Interact to see
Advertisement

NXTC vs REPL

Header iconNXTC vs REPL Comparison
Open Charts NXTC vs REPLBanner chart's image
NextCure
Price$0.51
Change-$0.00 (-0.00%)
Volume$90.81K
Capitalization14.24M
Replimune Group
Price$8.35
Change-$0.41 (-4.68%)
Volume$1.46M
Capitalization643.67M
NXTC vs REPL Comparison Chart
Loading...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NXTC vs. REPL commentary
May 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NXTC is a Buy and REPL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 26, 2025
Stock price -- (NXTC: $0.51 vs. REPL: $8.35)
Brand notoriety: NXTC and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NXTC: 48% vs. REPL: 132%
Market capitalization -- NXTC: $14.24M vs. REPL: $643.67M
NXTC [@Biotechnology] is valued at $14.24M. REPL’s [@Biotechnology] market capitalization is $643.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $297.63B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REPL’s FA Score shows that 1 FA rating(s) are green whileNXTC’s FA Score has 1 green FA rating(s).

  • REPL’s FA Score: 1 green, 4 red.
  • NXTC’s FA Score: 1 green, 4 red.
According to our system of comparison, both REPL and NXTC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NXTC’s TA Score shows that 6 TA indicator(s) are bullish while REPL’s TA Score has 6 bullish TA indicator(s).

  • NXTC’s TA Score: 6 bullish, 3 bearish.
  • REPL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NXTC is a better buy in the short-term than REPL.

Price Growth

NXTC (@Biotechnology) experienced а +15.94% price change this week, while REPL (@Biotechnology) price change was +6.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

NXTC is expected to report earnings on Jul 31, 2025.

REPL is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($644M) has a higher market cap than NXTC($14.2M). REPL YTD gains are higher at: -31.049 vs. NXTC (-34.137). NXTC has higher annual earnings (EBITDA): -50.34M vs. REPL (-216.51M). REPL has more cash in the bank: 537M vs. NXTC (55.9M). NXTC has less debt than REPL: NXTC (4.91M) vs REPL (76M). NXTC (0) and REPL (0) have equivalent revenues.
NXTCREPLNXTC / REPL
Capitalization14.2M644M2%
EBITDA-50.34M-216.51M23%
Gain YTD-34.137-31.049110%
P/E RatioN/AN/A-
Revenue00-
Total Cash55.9M537M10%
Total Debt4.91M76M6%
FUNDAMENTALS RATINGS
REPL vs NXTC: Fundamental Ratings
REPL
NXTC
OUTLOOK RATING
1..100
2021
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
6464
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NXTC's Valuation (14) in the Biotechnology industry is in the same range as REPL (25). This means that NXTC’s stock grew similarly to REPL’s over the last 12 months.

NXTC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as REPL (100). This means that NXTC’s stock grew similarly to REPL’s over the last 12 months.

REPL's SMR Rating (95) in the Biotechnology industry is in the same range as NXTC (100). This means that REPL’s stock grew similarly to NXTC’s over the last 12 months.

REPL's Price Growth Rating (64) in the Biotechnology industry is in the same range as NXTC (64). This means that REPL’s stock grew similarly to NXTC’s over the last 12 months.

REPL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NXTC (100). This means that REPL’s stock grew similarly to NXTC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NXTCREPL
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 6 days ago
75%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 12 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
74%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GRSRX52.990.26
+0.49%
Cohen & Steers Global Realty R
VGLSX10.18N/A
N/A
VALIC Company I Global Strategy
IMOWX24.37-0.05
-0.20%
Voya MidCap Opportunities W
NBGAX58.71-0.23
-0.39%
Neuberger Berman Genesis Adv
QNTIX35.25-0.17
-0.48%
Meeder Sector Rotation Institutional

NXTC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NXTC has been loosely correlated with CYTK. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NXTC jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NXTC
1D Price
Change %
NXTC100%
+0.28%
CYTK - NXTC
37%
Loosely correlated
+0.18%
ACET - NXTC
35%
Loosely correlated
-3.49%
ORMP - NXTC
33%
Poorly correlated
+0.47%
GOSS - NXTC
32%
Poorly correlated
+3.45%
SRPT - NXTC
29%
Poorly correlated
-2.29%
More

REPL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with ELVAF. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
-4.68%
ELVAF - REPL
60%
Loosely correlated
N/A
RCKT - REPL
51%
Loosely correlated
-4.86%
SNDX - REPL
47%
Loosely correlated
-8.88%
KYMR - REPL
45%
Loosely correlated
-2.12%
IDYA - REPL
44%
Loosely correlated
-1.72%
More